Mark C. Willingham

40.3k citations

425 papers · 33.5k indexed · 7 hit papers · h-index 90

Impact in

Oncology top 0.1%
- Drug Transport and Resistance Mechanisms
Cell Biology top 0.05%
- Cellular transport and secretion

Papers in

Biotechnology 58
- Transgenic Plants and Applications 41
Cell Biology 77
- Cellular transport and secretion 45

Co-authors: Ira Pastan Michael M. Gottesman I Pastan Frederick R. Maxfield F Thiébaut Hironobu Hamada T Tsuruo Sheue-yann Cheng
Journals: Proceedings of the National Academy of Sciences (36 papers)Journal of Histochemistry & Cytochemistry (32 papers)Journal of Biological Chemistry (25 papers)Cell (15 papers)Experimental Cell Research (14 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Mark C. Willingham

422 papers receiving 31.6k citations

Hit Papers

7 papers align trajectories log scale

Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. 1989 · 507 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1989 Journal of Histochemistry & Cytochemistry
1989 JNCI Journal of the National Cancer Institute
1987 Proceedings of the National Academy of Sciences
1982 Proceedings of the National Academy of Sciences
1980 Journal of Biological Chemistry
1980 Nature
1978 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Mark C. Willingham

Since Specialization

Citations

This map shows the geographic impact of Mark C. Willingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Willingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Willingham more than expected).

Fields of papers citing papers by Mark C. Willingham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Willingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Willingham. The network helps show where Mark C. Willingham may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark C. Willingham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark C. Willingham Line = papers co-authored together Mark C. Willingham links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study BMJ ·Hannah Whittaker, Stefan Hansson, TONY POMBO, Constantinos Kallis, Ann Morgan, Kumiko Fumisawa, Mark C. Willingham, Ю. Ю. Герасименко, Jennifer K Quint	2021	36
2	Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model Clinical Cancer Research ·Xuguang Zhu, Keisuke Enomoto, Li Zhao, Yuelin J. Zhu, Mark C. Willingham, Paul Meltzer, Jun Qi, Sheue-yann Cheng	2016	44
3	Inhibition of Tumorigenesis by the Thyroid Hormone Receptor β in Xenograft Models Thyroid ·Won Gu Kim, Li Zhao, Dong Wook Kim, Mark C. Willingham, Sheue-yann Cheng	2013	39
4	AGR2 Is a Novel Surface Antigen That Promotes the Dissemination of Pancreatic Cancer Cells through Regulation of Cathepsins B and D Cancer Research ·Laurent Dumartin, Hannah J. Whiteman, Mark C. Willingham, Deepak Hariharan, Branko Dmitrović, Christine A. Iacobuzio–Donahue, Teresa A. Brentnall, Mary P. Bronner, Roger Feakins, John F. Timms, Caroline H. Brennan, Nicholas R. Lemoine, Tatjana Crnogorac‐Jurcevic	2011	118
5	In situ Vaccination Combined with Androgen Ablation and Regulatory T-Cell Depletion Reduces Castration-Resistant Tumor Burden in Prostate-Specific Pten Knockout Mice Cancer Research ·Nampak N M Nanre, Endre Prakfalvi, Shuai Tang, Mark C. Willingham, Janet A. Tooze, Purnima Dubey	2010	33
6	Critical Roles of DMP1 in Human Epidermal Growth Factor Receptor 2/neu-Arf-p53 Signaling and Breast Cancer Development Cancer Research ·Pankaj Taneja, Dejan Maglic, Fumitake Kai, Takayuki Sugiyama, Robert D. Kendig, Donna P. Frazier, Mark C. Willingham, Kazushi Inoue	2010	33
7	Inhibition of Acyl-Coenzyme A:Cholesterol Acyltransferase 2 (ACAT2) Prevents Dietary Cholesterol-associated Steatosis by Enhancing Hepatic Triglyceride Mobilization Journal of Biological Chemistry ·Heather M. Alger, J. Mark Brown, Janet K. Sawyer, Kathryn L. Kelley, Ramesh Shah, Martha D. Wilson, Mark C. Willingham, Lawrence L. Rudel	2010	67
8	Cancer-Specific Transgene Expression Mediated by Systemic Injection of Nanoparticles Cancer Research ·Edward J. Chisholm, Georges Vassaux, Pilar Martín‐Duque, Raphaël Chèvre, Olivier Lambert, Bruno Pitard, Chien-Lan Hsueh, Mark C. Willingham, Jerome Burnet, Zirwa Javed Dr Meha Siddiqui, Ming‐Shen Dai, Ghassan Alusi, Stephen J. Mather, Jamaal Hyder, Ijeoma F. Uchegbu, Andreas G. Schätzlein, Patrick Baril	2009	55
9	Topology of NGEP, a Prostate-Specific Cell:Cell Junction Protein Widely Expressed in Many Cancers of Different Grade Level Cancer Research ·Sudipto Das, Yoonsoo Hahn, Dawn A. Walker, Satoshi Nagata, Mark C. Willingham, Donna M. Peehl, Tapan K. Bera, Byung Kook Lee, Ira Pastan	2008	57
10	The Role of S100P in the Invasion of Pancreatic Cancer Cells Is Mediated through Cytoskeletal Changes and Regulation of Cathepsin D Cancer Research ·Hannah J. Whiteman, Mark C. Willingham, Sally E. Dowen, Sayka Barry, John F. Timms, Nicholas R. Lemoine, Tatjana Crnogorac‐Jurcevic	2007	85
11	Monitoring changes in nisin susceptibility of Listeria monocytogenes Scott A as an indicator of growth phase using FACS Journal of Microbiological Methods ·Mark C. Willingham, Giulia Caron, David C. James, C. Mark Smales, Gary K. Robinson	2005	12
12	Localization of Mesothelin in Epithelial Ovarian Cancer Applied immunohistochemistry & molecular morphology ·Raffit Hassan, Robert J. Kreitman, Ira Pastan, Mark C. Willingham	2005	147
13	Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors Oncogene ·Tagallamudi Nm, Shantaram Bharadwaj, Edward A. Levine, Mark C. Willingham, Randolph L. Geary, Tim Kute, G. L. Prasad	2003	119
14	Inhibition of TNF-α Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2 The Journal of Immunology ·Masanori Onda, Mark C. Willingham, Qingcheng Wang, Robert J. Kreitman, Yasuo Tsutsumi, Satoshi Nagata, Ira Pastan	2000	53
15	Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells. PubMed ·A.J. Trimboli, B. Moseley Waite, Gen‐ichi Atsumi, Alfred N. Fonteh, Andrew M. Namen, Carl E. Clay, Tim Kute, Kevin P. High, Mark C. Willingham, Floyd H. Chilton	1999	28
16	Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells Carcinogenesis ·Carl E. Clay, Andrew M. Namen, Gen‐ichi Atsumi, Mark C. Willingham, Kevin P. High, Timothy E. Kute, Anthony J. Trimboli, Alfred N. Fonteh, Paul A. Dawson, Floyd H. Chilton	1999	157
17	Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. Journal of Clinical Investigation ·Waldemar Debinski, B. Karlsson, Leif Lindholm, Clay B. Siegall, Mark C. Willingham, David FitzGerald, Ira Pastan	1992	31
18	Magnetic-Affinity Cell Sorting of Human Multidrug-Resistant Cells JNCI Journal of the National Cancer Institute ·P.K. Rajan, T. Tsuruo, Susan E. Kane, Mark C. Willingham, Bruce H. Howard, Michael M. Gottesman, Ira Pastan	1991	13
19	Use of colloidal gold cytochemistry in the study of the basic cell biology of cancer American Journal of Anatomy ·Mark C. Willingham	1989	2
20	142 The Multidrug Resistance Phenotype in Mutant Human Carcinoma Cells : Cytochemical Detection of Altered Accumulation and Efflux of Daunomycin. : ACTA HISTOCHEMICA ET CYTOCHEMICA ·Mark C. Willingham, Marilyn M. Cornwell, J. Lohuizen van, Ira Pastan	1986	1

About Mark C. Willingham

Mark C. Willingham is a scholar working on Biotechnology, Cell Biology, Immunology, Molecular Biology and Oncology, having authored 425 papers that have together received 33.5k indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (66 papers), Cellular transport and secretion (45 papers), Monoclonal and Polyclonal Antibodies Research (42 papers), Transgenic Plants and Applications (41 papers), Lipid Membrane Structure and Behavior (34 papers), Virus-based gene therapy research (30 papers), Cancer-related Molecular Pathways (25 papers) and Thyroid Disorders and Treatments (25 papers). The work is most often cited by research in Oncology (9.4k citations), Cell Biology (4.7k citations), Immunology (5.5k citations), Molecular Biology (17.6k citations) and Biotechnology (2.1k citations). Mark C. Willingham has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Ira Pastan, Michael M. Gottesman, I Pastan, Frederick R. Maxfield, F Thiébaut, Hironobu Hamada, T Tsuruo, Sheue-yann Cheng, Glenn Merlino and John A. Hanover. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Histochemistry & Cytochemistry, Journal of Biological Chemistry, Cell and Experimental Cell Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact